MA52371A - Méthodes de traitement d'infections dues aux coronaviridae - Google Patents

Méthodes de traitement d'infections dues aux coronaviridae

Info

Publication number
MA52371A
MA52371A MA052371A MA52371A MA52371A MA 52371 A MA52371 A MA 52371A MA 052371 A MA052371 A MA 052371A MA 52371 A MA52371 A MA 52371A MA 52371 A MA52371 A MA 52371A
Authority
MA
Morocco
Prior art keywords
methods
coronaviridae infections
treating coronaviridae
treating
infections
Prior art date
Application number
MA052371A
Other languages
English (en)
Inventor
Michael O'neil Hanrahan Clarke
Joy Yang Feng
Robert Jordan
Richard L Mackman
Adrian S Ray
Dustin Siegel
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MA52371A publication Critical patent/MA52371A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA052371A 2015-09-16 2016-09-16 Méthodes de traitement d'infections dues aux coronaviridae MA52371A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562219302P 2015-09-16 2015-09-16
US201562239696P 2015-10-09 2015-10-09

Publications (1)

Publication Number Publication Date
MA52371A true MA52371A (fr) 2021-09-22

Family

ID=56997582

Family Applications (2)

Application Number Title Priority Date Filing Date
MA042819A MA42819A (fr) 2015-09-16 2016-09-16 Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae
MA052371A MA52371A (fr) 2015-09-16 2016-09-16 Méthodes de traitement d'infections dues aux coronaviridae

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA042819A MA42819A (fr) 2015-09-16 2016-09-16 Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae

Country Status (24)

Country Link
US (5) US10251904B2 (fr)
EP (3) EP3785717B1 (fr)
JP (6) JP6742403B2 (fr)
KR (1) KR20180050742A (fr)
CN (5) CN116617233A (fr)
AU (4) AU2016323604B2 (fr)
BR (2) BR112018005048B8 (fr)
CA (1) CA2998189C (fr)
CY (2) CY1125089T1 (fr)
DK (2) DK3349758T3 (fr)
EA (1) EA038141B1 (fr)
ES (2) ES2918585T3 (fr)
HK (1) HK1257628A1 (fr)
HR (2) HRP20220740T1 (fr)
HU (2) HUE057928T2 (fr)
LT (2) LT3349758T (fr)
MA (2) MA42819A (fr)
MX (2) MX394858B (fr)
PL (2) PL3785717T3 (fr)
PT (2) PT3785717T (fr)
SG (2) SG10202001878WA (fr)
SI (2) SI3349758T1 (fr)
TW (1) TW201733595A (fr)
WO (1) WO2017049060A1 (fr)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ599404A (en) 2009-09-21 2014-02-28 Gilead Sciences Inc Processes and intermediates for the preparation of 1’-substituted carba-nucleoside analogs
PT2595980E (pt) 2010-07-22 2014-11-27 Gilead Sciences Inc Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae
TWI698444B (zh) 2014-10-29 2020-07-11 美商基利科學股份有限公司 製備核糖苷的方法
WO2016106050A1 (fr) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine, ses dérivés et utilisations anti-virales
DK3349758T3 (da) 2015-09-16 2022-06-13 Gilead Sciences Inc Fremgangsmåder til behandling af arenaviridae-virusinfektioner
WO2018089306A1 (fr) 2016-11-10 2018-05-17 Oyagen, Inc. Méthodes de traitement et d'inhibition d'une infection par le virus ebola
CN110869028B (zh) * 2017-03-14 2023-01-20 吉利德科学公司 治疗猫冠状病毒感染的方法
EP4219513A1 (fr) * 2017-05-01 2023-08-02 Gilead Sciences, Inc. Forme cristalline de (s)-2-éthylbutyl 2-((s)-((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f! [1,2,4 triazin-7-yl)-5-cyano-3,4-dihydroxy tétrahydrofuranne 2-yl)méthoxy)(phénoxy) phosphoryl)amino)propanoate
CN111093627B (zh) * 2017-07-11 2024-03-08 吉利德科学公司 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
WO2019053696A1 (fr) * 2017-09-18 2019-03-21 Alios Biopharma, Inc. Nucléosides substitués, nucléotides et analogues de ceux-ci
RU2020116571A (ru) 2017-12-07 2021-11-22 Эмори Юниверсити N4-гидроксицитидин и производные и связанные с этим противовирусные применения
CN110724174B (zh) * 2019-09-10 2021-02-05 广州六顺生物科技股份有限公司 吡咯并三嗪类化合物、组合物及其应用
CN111265532A (zh) * 2020-01-21 2020-06-12 中国人民解放军军事科学院军事医学研究院 取代氨基丙酸酯类化合物在治疗2019-nCoV感染中的应用
KR20220132608A (ko) 2020-01-27 2022-09-30 길리애드 사이언시즈, 인코포레이티드 SARS CoV-2 감염증을 치료하기 위한 방법
WO2021152595A1 (fr) * 2020-01-29 2021-08-05 Memed Diagnostics Ltd. Méthodes de diagnostic et de classification d'infections virales
WO2021158248A1 (fr) * 2020-02-04 2021-08-12 Oyagen, Inc. Méthodes de traitement d'infections à coronavirus
TWI794742B (zh) * 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
CN113292565B (zh) * 2020-02-24 2023-01-31 浙江森科建设有限公司 核苷类化合物及其制备方法和应用
WO2021168930A1 (fr) * 2020-02-25 2021-09-02 顾世海 Comprimé de remdésivir et son procédé de préparation
CN111187269A (zh) * 2020-02-27 2020-05-22 江苏阿尔法药业有限公司 一种瑞德西韦中间体的合成方法
WO2021173713A1 (fr) * 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Composés hautement actifs contre la covid-19
CN111205294B (zh) * 2020-02-27 2021-10-01 江苏阿尔法药业股份有限公司 一种瑞德西韦中间体的制备方法
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CN111233929B (zh) * 2020-02-28 2023-02-28 成都阿奇生物医药科技有限公司 一种核苷类似物的氘代物及其制备方法和用途
US20230124467A1 (en) * 2020-03-03 2023-04-20 Mios Pharmaceuticals Limited Compounds and methods for treating diseases and/or conditions caused by coronavirus
CN113336758B (zh) * 2020-03-03 2022-08-19 北京桦冠医药科技有限公司 化合物7-碘吡咯并[2，1-f][1，2，4]三嗪-4-胺的一种新合成方法
CN111116656A (zh) * 2020-03-04 2020-05-08 江苏福瑞康泰药业有限公司 一种瑞德西韦的制备方法
CN111269248A (zh) * 2020-03-05 2020-06-12 江苏福瑞康泰药业有限公司 一种核苷氨基磷酸酯类药物母液回收的新方法
CN111233870A (zh) * 2020-03-11 2020-06-05 中国科学技术大学 用于快速制备瑞德西韦药物中间体的方法
TWI785528B (zh) 2020-03-12 2022-12-01 美商基利科學股份有限公司 1’-氰基核苷之製備方法
CN111393478B (zh) * 2020-03-13 2023-05-26 深圳市宝安区新材料研究院 一种瑞德西韦的合成方法
WO2021186438A1 (fr) * 2020-03-16 2021-09-23 Bar-Ilan University Molécules ciblant des protéines de coronavirus et leurs utilisations en tant que « cocktail » antiviral
CN113402546A (zh) * 2020-03-17 2021-09-17 浙江四维医药科技有限公司 一种瑞德西韦磷酸中间体尾链动态动力学拆分方法
WO2021195661A1 (fr) * 2020-03-23 2021-09-30 Gregg John M H Composés antiviraux et leurs procédés d'administration
CN113493480B (zh) * 2020-04-03 2025-04-15 南京正大天晴制药有限公司 一种瑞德西韦异构体的制备及其分析方法
JP7482250B2 (ja) 2020-04-06 2024-05-13 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノ置換カルバヌクレオシド類似体の吸入製剤
CN116036031A (zh) * 2020-04-07 2023-05-02 齐鲁制药有限公司 一种含有瑞德西韦的药物组合物
WO2021208910A1 (fr) * 2020-04-13 2021-10-21 山东华铂凯盛生物科技有限公司 Préparation de polymère pour le traitement d'infections virales, procédé de préparation et utilisation correspondants
WO2021211757A1 (fr) * 2020-04-14 2021-10-21 Oyagen, Inc. MÉTHODES DE TRAITEMENT D'INFECTIONS À ARÉNAVIRIDÉS<i />
CN111848679A (zh) * 2020-04-17 2020-10-30 山东科巢生物制药有限公司 一种利用微通道反应技术合成瑞德西韦的方法
CN113521020B (zh) * 2020-04-18 2023-05-02 齐鲁制药有限公司 一种含有水溶性酸的瑞德西韦固体剂型
CN112778310B (zh) * 2020-04-20 2025-05-30 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN111393243B (zh) * 2020-04-22 2022-12-13 深圳市宝安区新材料研究院 一种磷手性核苷类药物的合成方法及该方法得到的药物
CN111440176B (zh) * 2020-04-28 2022-04-26 江苏大学 金属配合物促进的瑞德西韦中间体的合成方法
CN111494349A (zh) * 2020-04-30 2020-08-07 中国人民解放军空军军医大学 一种瑞德西韦口腔速溶膜及制备方法
CN113633617A (zh) * 2020-05-11 2021-11-12 齐鲁制药有限公司 一种含有瑞德西韦的固体分散体、固体剂型及制备方法
WO2021234554A2 (fr) * 2020-05-20 2021-11-25 Lyrus Life Sciences Pvt Ltd Nouvelle composition pour le traitement d'infections virales
WO2021237109A1 (fr) 2020-05-22 2021-11-25 Trailhead Biosystems Inc. Polythérapie pour le traitement d'infections virales
IN202011022634A (fr) * 2020-05-29 2020-10-09 Jubilant Generics Limited
EP4157272B1 (fr) 2020-05-29 2025-07-02 Gilead Sciences, Inc. Remdésivir pour le traitement des infections virales
US11020349B1 (en) * 2020-07-14 2021-06-01 Jubilant Generics Limited Transmucosal dosage forms of remdesivir
EP3915548A1 (fr) 2020-05-29 2021-12-01 Jubilant Generics Limited Compositions pharmaceutiques transmucosales de médicaments antiviraux
CN111620909B (zh) * 2020-06-05 2022-12-02 广东中科药物研究有限公司 一种瑞德西韦的前体药物及其制备方法与应用
WO2021248229A1 (fr) * 2020-06-11 2021-12-16 Apotex Inc Nouvelle forme cristalline de remdésivir
WO2021262715A1 (fr) * 2020-06-23 2021-12-30 Anovent Pharmaceutical (U.S.), Llc Formulation pharmaceutique contenant des métabolites actifs de remdésivir ou son analogue pour inhalation
IL299202A (en) * 2020-06-24 2023-02-01 Gilead Sciences Inc 1'-cyano nucleoside analogs and uses thereof
CN111732618A (zh) * 2020-07-03 2020-10-02 镇江巨杰新材料技术研发中心(有限合伙) 瑞德西韦关键片段的合成方法
WO2022008642A1 (fr) 2020-07-08 2022-01-13 Apeiron Biologics Ag Traitement d'une infection par le sras-cov-2 avec une combinaison de cibles
CN111875638A (zh) * 2020-07-16 2020-11-03 江苏省原子医学研究所 一种瑞德西韦衍生物的制备方法、瑞德西韦衍生物及其应用
CN111961079A (zh) * 2020-07-17 2020-11-20 南京正济医药研究有限公司 一种瑞德西韦有关物质及其制备方法和应用
WO2022020886A1 (fr) * 2020-07-27 2022-02-03 Microbio Pty Ltd Procédé de détection de réplication virale
JP7559223B2 (ja) 2020-08-24 2024-10-01 ギリアード サイエンシーズ， インコーポレイテッド リン脂質化合物及びその使用
US11926645B2 (en) * 2020-08-27 2024-03-12 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
CN112358504A (zh) * 2020-09-28 2021-02-12 南京正济医药研究有限公司 一种瑞德西韦有关物质及其制备方法和用途
CN112194680A (zh) * 2020-09-29 2021-01-08 佛山科学技术学院 核苷酸氨基磷酸酯化合物、其药物组合物及其制备方法和应用
CN112194681A (zh) * 2020-09-29 2021-01-08 佛山科学技术学院 核苷酸长链氨基磷酸酯化合物、其药物组合物及其制备方法和应用
US11612614B2 (en) * 2020-10-20 2023-03-28 Anzalp Pharmasolutions Pvt. Ltd. Isomorphs of Remdesivir and methods for synthesis of same
CN112300236A (zh) * 2020-10-21 2021-02-02 佛山科学技术学院 核苷酸混合氨基磷酸酯化合物、其药物组合物及其应用
JP7711900B2 (ja) * 2020-10-26 2025-07-23 蘇州旺山旺水生物医薬股▲ふん▼有限公司 ヌクレオシド類似体の塩及びその結晶形、医薬組成物並びに用途
CN113754665B (zh) * 2020-12-30 2022-08-19 南方科技大学 一种核苷类化合物的制备方法
CN116370479B (zh) * 2020-12-30 2024-02-13 南方科技大学 化合物atv014在制备用于治疗新冠病毒感染的产品中的用途
US12558364B2 (en) * 2021-01-20 2026-02-24 Regents Of The University Of Minnesota Next generation remdesivir antivirals
US11998562B2 (en) 2021-01-25 2024-06-04 University Of South Florida Ophthalmological formulations for the prevention of a coronavirus infection
WO2022164941A1 (fr) 2021-01-26 2022-08-04 Atea Pharmaceuticals, Inc. Forme morphique avantageuse de sel hémi-sulfate d'at-527
WO2022166581A1 (fr) * 2021-02-07 2022-08-11 石家庄迪斯凯威医药科技有限公司 Dérivé nucléotidique, composite pharmaceutique de celui-ci et son utilisation
CN115109077A (zh) * 2021-03-18 2022-09-27 上海医药集团股份有限公司 瑞德西韦中间体的制备方法
CN113105504B (zh) * 2021-03-30 2024-06-04 澳门科技大学 Remdesivir衍生物、其类似物及其制备方法与应用
AU2022256476B2 (en) 2021-04-16 2025-06-05 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
AU2022291927A1 (en) 2021-06-17 2024-01-04 Atea Pharmaceuticals, Inc. Advantageous anti-hcv combination therapy
CA3228162A1 (fr) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Composes phospholipidiques et leurs procedes de production et d'utilisation
CN115947758A (zh) * 2021-10-07 2023-04-11 南京知和医药科技有限公司 一种核苷酸衍生物及其药物组合物和用途
CN114213366A (zh) * 2022-01-17 2022-03-22 江西师范大学 一种氟代糖内酯合成方法
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
WO2023194840A1 (fr) 2022-04-05 2023-10-12 Unichem Laboratories Limited Composés tricycliques substitués et leur utilisation dans la covid-19
AU2023261450A1 (en) * 2022-04-25 2024-11-14 Miracure Biotechnology Limited Nucleoside drug for treating or preventing coronavirus infection, and use thereof
WO2023239665A1 (fr) * 2022-06-06 2023-12-14 Gilead Sciences, Inc. Méthodes de traitement d'infections virales y compris le sars-cov-2
EP4547334A1 (fr) * 2022-06-29 2025-05-07 Gilead Sciences, Inc. Formes solides d'un analogue nucléosidique et leurs utilisations
EP4547665A1 (fr) 2022-06-30 2025-05-07 Gilead Sciences, Inc. Formes solides d'un analogue nucléosidique et leurs utilisations
US11655255B2 (en) 2022-10-17 2023-05-23 Sph No.1 Biochemical & Pharmaceutical Co., Ltd. Method for catalytic asymmetric synthesis of phosphorus-stereogenic (P-stereogenic) nucleoside derivative and catalyst used therein
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
JP2025540572A (ja) 2022-11-18 2025-12-16 ギリアード サイエンシーズ， インコーポレイテッド ポックスウイルス感染を治療する方法
CN118165034A (zh) * 2022-12-09 2024-06-11 深圳市塔吉瑞生物医药有限公司 核苷酸类化合物及其组合物及用途
CN116589510B (zh) * 2023-04-20 2025-08-26 安徽大学 一种氟代苄基核糖中间体的制备方法与应用
CN116410228B (zh) * 2023-05-04 2025-10-31 南京颐媛生物医学研究院有限公司 一种抗冠状病毒核苷类化合物的制备方法及其应用
CN117126199B (zh) * 2023-05-17 2024-12-06 江西师范大学 一种氟代瑞德西韦合成方法

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
ES2083580T3 (es) 1990-06-13 1996-04-16 Arnold Glazier Profarmacos de fosforo.
DK0481214T3 (da) 1990-09-14 1999-02-22 Acad Of Science Czech Republic Prolægemidler af phosphonater
JPH1017629A (ja) 1996-07-04 1998-01-20 Kayaku Akzo Kk ハードコート用樹脂組成物及びその硬化方法
US6887707B2 (en) 1996-10-28 2005-05-03 University Of Washington Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
KR20010041533A (ko) 1998-03-03 2001-05-25 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 (2ｅ)-5-아미노-5-메틸헥스-2-엔오산ｎ-메틸-ｎ-((1ｒ)-1-(ｎ-메틸-ｎ-((1ｒ)-1-(메틸카르바모일)-2-페닐에틸)카르바모일)-2-(2-나프틸)에틸)아미드의신규한 염 형태
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US6475985B1 (en) 1998-03-27 2002-11-05 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
DE69936998T2 (de) 1998-10-16 2008-05-21 Merck Sharp & Dohme Ltd., Hoddesdon Pyrazolotriazinderivate als gaba-rezeptorliganden
DE19912636A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
WO2000075157A1 (fr) 1999-06-03 2000-12-14 Abbott Laboratories Synthese d'oligonucleotides utilisant des acides de lewis comme activateurs
AUPQ105499A0 (en) 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
WO2001019375A1 (fr) 1999-09-15 2001-03-22 Biocryst Pharmaceuticals, Inc. Procede permettant d'inhiber la proliferation d'un lymphocyte t
CA2389745C (fr) 1999-11-04 2010-03-23 Shire Biochem Inc. Procede de traitement ou de prevention de l'infection virale par flaviviridae faisant appel a des analogues des nucleosides
SK11922002A3 (sk) 2000-02-18 2003-06-03 Shire Biochem Inc. Použitie analógov nukleozidov na liečenie alebo prevenciu infekcií spôsobených flavivírusom
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
PL359169A1 (en) 2000-05-26 2004-08-23 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
HRP20030047B1 (hr) 2000-07-21 2016-02-26 Gilead Sciences, Inc. Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
KR20090089922A (ko) 2000-10-18 2009-08-24 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
MXPA03006514A (es) 2001-01-22 2004-12-02 Merck & Co Inc Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico.
DE10145223A1 (de) 2001-09-13 2003-04-03 Basf Ag Verfahren zur Herstellung von meso-Zeaxanthin
WO2003026675A1 (fr) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Procedes et compositions pour traiter des flavivirus et des pestivirus au moyen d'un nucleoside modifie en position 4'
AT410792B (de) 2001-12-28 2003-07-25 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von geschützten, enantiomeren-angereicherten cyanhydrinen durch in-situ-derivatisierung
RU2004128943A (ru) 2002-02-28 2005-04-20 Байота, Инк. (Us) Средства, имитирующие нуклеотиды, и их пролекарственные формы
WO2003073989A2 (fr) 2002-02-28 2003-09-12 Biota, Inc. Analogues de nucleoside 5'-monophosphate et leurs promedicaments
US20040138170A1 (en) 2002-03-06 2004-07-15 Montgomery John A. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
GB0210124D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0210127D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
BR0309581A (pt) 2002-05-06 2005-03-29 Genelabs Tech Inc Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
AU2003233667A1 (en) 2002-05-23 2003-12-12 Biocryst Pharmaceuticals, Inc. Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof
AU2003298658A1 (en) 2002-11-15 2004-06-15 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
SG182849A1 (en) 2003-04-25 2012-08-30 Gilead Sciences Inc Antiviral phosphonate analogs
EP1646371A4 (fr) 2003-06-26 2010-09-22 Biotron Ltd Compositions et methodes antivirales
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
ATE478886T1 (de) 2003-07-25 2010-09-15 Idenix Pharmaceuticals Inc Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
WO2005021568A2 (fr) 2003-08-27 2005-03-10 Biota, Inc. Nouveau nucleosides ou nucleotides tricycliques utillises comme agents therapeutiques
EA011158B1 (ru) 2004-03-16 2009-02-27 Бёрингер Ингельхайм Интернациональ Гмбх Замещённые глюкопиранозилом бензольные производные, содержащие эти соединения лекарственные средства, их применение и способ их получения
WO2005123087A2 (fr) 2004-06-15 2005-12-29 Merck & Co., Inc. Analogues nucleosidiques de c-purine, servant d'inhibiteurs d'arn-polymerase virale arn-dependante
US7560434B2 (en) 2004-06-22 2009-07-14 Biocryst Pharmaceuticals, Inc. AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
ES2725457T3 (es) 2004-09-14 2019-09-24 Gilead Pharmasset Llc Preparación de ribofuranosil pirimidinas y purinas 2'fluoro-2'-alquil-sustituidas u otras opcionalmente sustituidas y sus derivados
CN101043893A (zh) 2004-10-21 2007-09-26 默克公司 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷
AU2005317081A1 (en) 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of RNA-dependent RNA viral infection
AU2005302448B2 (en) 2004-10-29 2012-07-19 Biocryst Pharmaceuticals, Inc. Therapeutic furopyrimidines and thienopyrimidines
JP2008524162A (ja) 2004-12-16 2008-07-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換ベンゼン誘導体、該化合物を含む薬物、その使用及びその製造方法
AU2006222563A1 (en) 2005-03-08 2006-09-14 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
CA2602533A1 (fr) 2005-03-29 2006-10-05 Biocryst Pharmaceuticals, Inc. Therapies contre l'hepatite c
WO2006116557A1 (fr) 2005-04-25 2006-11-02 Genelabs Technologies, Inc. Composes nucleosides pour le traitement d’infections virales
WO2006121820A1 (fr) 2005-05-05 2006-11-16 Valeant Research & Development Promedicaments de phosphoramidate pour traitement d'infections virales
WO2007027248A2 (fr) 2005-05-16 2007-03-08 Valeant Research & Development Analogues de nucleoside cyclique 3', 5' pour le traitement du virus de l'hepatite c (vhc)
US8669280B2 (en) 2005-06-24 2014-03-11 Biotron Limited Antiviral compounds and methods
ES2436404T3 (es) 2005-10-03 2013-12-30 University Health Network Inhibidores ODCasa para el tratamiento de malaria
EP1945222B1 (fr) 2005-11-02 2012-12-26 Bayer Pharma Aktiengesellschaft Derives pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines comme inhibiteurs de la igf-1r kinase pour le traitement des cancers et d'autres maladies hyperproliferatives
SI1954264T1 (sl) 2005-12-01 2010-01-29 Basilea Pharmaceutica Ag Postopek priprave intermediatov epoksibutanola
BRPI0619146A2 (pt) 2005-12-02 2011-09-13 Bayer Pharmaceuticals Corp derivados de 4-amino-pirroltriazina substituìda úteis no tratamento de disordens e doenças hiperproliferativas associadas com angiogênesis
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
BRPI0619563A2 (pt) 2005-12-09 2011-10-04 Pharmasset Inc nucleosìdeos antivirais
JP5112328B2 (ja) 2005-12-09 2013-01-09 バジリア ファルマスーチカ アーゲー 重度の皮膚科障害の局所的処置のための４−オキソ（イソ）トレチノイン
EP1987050A2 (fr) 2006-02-14 2008-11-05 Merck & Co., Inc. Phosphoramidates d'aryle nucleosidiques pour le traitement d'infections ribovirales dependantes de l'arn
WO2007097991A2 (fr) 2006-02-16 2007-08-30 Pharmasset, Inc. Méthodes et trousses pour administrer des agents antiviraux
DE102006015378A1 (de) 2006-04-03 2007-10-04 Ludwig-Maximilians-Universität München Verfahren zur Synthese von Organoelementverbindungen
CL2007001427A1 (es) 2006-05-22 2008-05-16 Novartis Ag Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
WO2008005542A2 (fr) 2006-07-07 2008-01-10 Gilead Sciences, Inc., Composés antiviraux à base de phosphinate
US20080161324A1 (en) 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
AR063569A1 (es) 2006-11-06 2009-02-04 Boehringer Ingelheim Int Derivados de benzil- benzonitrilo sustituidos con glucopiranosilo medicamentos que contienen a compuestos de este tipo su uso u procedimiento para su fabricacion
JP2010513484A (ja) 2006-12-20 2010-04-30 メルク・シャープ・エンド・ドーム・コーポレイション Ｒｎａ依存性ｒｎａウイルス感染治療用ヌクレオシド環状ホスホロアミデート
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
AU2007342367B2 (en) 2007-01-05 2012-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
NZ598927A (en) 2007-01-12 2013-09-27 Biocryst Pharm Inc Antiviral nucleoside analogs
WO2008116064A2 (fr) 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Composés hétérocycliques fusionnés utiles en tant que modulateurs de kinases
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
DK2155758T3 (da) 2007-05-10 2012-11-05 Biocryst Pharm Inc Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer
CN100532388C (zh) 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
ES2614269T3 (es) 2007-08-03 2017-05-30 Biotron Limited Procedimientos y composiciones antivíricas frente a la hepatitis C
KR101502533B1 (ko) 2007-11-22 2015-03-13 에스케이케미칼주식회사 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
US8227431B2 (en) 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
PL2280973T3 (pl) * 2008-04-23 2013-05-31 Gilead Sciences Inc Analogi karba-nukleozydowe do leczenia przeciwwirusowego
WO2010036407A2 (fr) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Analogues nucléosidiques antiviraux
EP2313102A2 (fr) 2008-07-03 2011-04-27 Biota Scientific Management Nucléosides bicycliques et nucléotides convenant comme agents thérapeutiques
BRPI1013643A2 (pt) 2009-02-10 2016-04-19 Gilead Sciences Inc análogos de carba-nucleosídeo para tratamento antiviral
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
WO2010108140A1 (fr) 2009-03-20 2010-09-23 Alios Biopharma, Inc. Nucleoside substitue et analogues nucleotidiques
MX2011009928A (es) 2009-03-24 2012-03-16 Biocryst Pharm Inc Sales farmaceuticas utiles de 7[(3r, 4r)-3-hidroxi-4-hidroximetil- pirrolidin-1-ilmetil]-3,5-dihidro-pirrol[3,2-d]pirimidin-4-ona.
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
KR20120051022A (ko) 2009-07-21 2012-05-21 길리애드 사이언시즈, 인코포레이티드 플라비비리데 바이러스의억제제
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
DK2480552T3 (en) 2009-09-21 2017-02-20 Gilead Sciences Inc 2 'FLUOROUS-SUBSTITUTED CARBA NUCLEOSIDE ANALYSIS FOR ANTIVIRAL TREATMENT
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
NZ599404A (en) 2009-09-21 2014-02-28 Gilead Sciences Inc Processes and intermediates for the preparation of 1’-substituted carba-nucleoside analogs
WO2011080568A2 (fr) 2009-12-28 2011-07-07 Development Center For Biotechnology Nouveaux composés de pyrimidine en tant qu'inhibiteurs de mtor et p13k
AP2012006535A0 (en) 2010-03-31 2012-10-31 Gilead Pharmasset Llc Stereoselective synthesis of phosphorous containing actives
TW201136945A (en) 2010-03-31 2011-11-01 Pharmasset Inc Purine nucleoside phosphoramidate
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
EA025311B1 (ru) 2010-07-19 2016-12-30 Гайлид Сайэнсиз, Инк. Способы получения диастереомерно чистых фосфорамидатных пролекарств
PT2595980E (pt) 2010-07-22 2014-11-27 Gilead Sciences Inc Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae
TW201305185A (zh) * 2010-09-13 2013-02-01 吉李德科學股份有限公司 用於抗病毒治療之２’－氟取代之碳－核苷類似物
SG188223A1 (en) 2010-09-20 2013-04-30 Gilead Sciences Inc 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
WO2012040127A1 (fr) * 2010-09-22 2012-03-29 Alios Biopharma, Inc. Analogues nucléotidiques substitués
LT2898885T (lt) 2010-10-15 2018-02-26 Biocryst Pharmaceuticals, Inc. Pirolopirimidino dariniai, skirti naudoti virusinių infekcijų gydymui
ES2716158T3 (es) 2010-11-30 2019-06-10 Gilead Pharmasset Llc 2'-spiro-nucleótidos para el tratamiento de hepatitis C
TW201306841A (zh) 2010-12-20 2013-02-16 Gilead Sciences Inc 治療ｃ型肝炎病毒（ｈｃｖ）之方法
EP2697241B1 (fr) 2011-04-13 2019-06-12 Gilead Sciences, Inc. Analogues de n-nucléoside de pyrimidine 1'-substitués pour un traitement antiviral
WO2012142085A1 (fr) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. Dérivés de nucléoside 2'-substitués et procédés d'utilisation de ceux-ci pour le traitement de maladies virales
ES2639122T3 (es) 2011-05-13 2017-10-25 Zoetis Services Llc Composiciones inmunogénicas de glucoproteína G de virus Hendra y Nipah
HRP20180237T4 (hr) 2011-09-16 2020-12-11 Gilead Pharmasset Llc Metode za liječenje hcv-a
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013084165A1 (fr) 2011-12-05 2013-06-13 Medivir Ab Inhibiteurs de vhc polymérase
US20130143835A1 (en) 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
EP2794630A4 (fr) 2011-12-22 2015-04-01 Alios Biopharma Inc Analogues de nucléotide phosphorothioate substitués
MD20140134A2 (ro) 2012-05-22 2015-04-30 Idenix Pharmaceuticals, Inc. Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice
US9556216B2 (en) 2012-08-31 2017-01-31 Novartis Ag 2′-Ethynyl nucleoside derivatives for treatment of viral infections
CA2881322A1 (fr) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag Heteroaryldihydropyrimidines d'acide 6-amine pour le traitement et la prophylaxie d'une infection par le virus de l'hepatite b
WO2014042433A2 (fr) 2012-09-14 2014-03-20 Kainos Medicine, Inc. Composés et compositions de modulation de l'activité du récepteur adénosine a3
MX2015005949A (es) * 2012-11-16 2015-09-08 Biocryst Pharm Inc Nucleosidos que contienen aza-azucar antiviral.
JP2016501200A (ja) 2012-11-19 2016-01-18 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ウイルス性疾患を処置するための２−アルキニル置換ヌクレオシド誘導体
US9243022B2 (en) 2012-12-21 2016-01-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9283242B2 (en) 2013-01-22 2016-03-15 Massachusetts Institute Of Technology Uses of dihydro bases
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
AU2014250762A1 (en) 2013-04-12 2015-10-29 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of HCV
US9542154B2 (en) 2013-06-25 2017-01-10 Intel Corporation Fused multiply add operations using bit masks
UA117375C2 (uk) 2013-09-04 2018-07-25 Медівір Аб Інгібітори полімерази hcv
MX377523B (es) 2013-09-11 2025-03-10 Inst Nat Sante Rech Med Metodos y composiciones farmaceuticas para el tratamiento de la infeccion por el virus de la hepatitis b.
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
PE20160686A1 (es) 2014-01-30 2016-07-23 Hoffmann La Roche Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infeccion por virus de la hepatitis b
PL3114128T3 (pl) 2014-03-07 2019-06-28 F. Hoffmann-La Roche Ag Nowe skondensowane w pozycji 6 heteroarylodihydropirymidyny stosowane w leczeniu i profilaktyce zakażenia wirusem zapalenia wątroby typu B
CN106459032B (zh) 2014-05-13 2019-04-05 豪夫迈·罗氏有限公司 治疗和预防乙型肝炎病毒感染的新的二氢喹嗪酮类
US9616076B2 (en) 2014-06-02 2017-04-11 The Board Of Regents Of The University Of Texas Systems Methods for treating viral infections using hydrogen sulfide donors
US9504701B2 (en) 2014-06-02 2016-11-29 The Board Of Regents Of The University Of Texas System Methods for treating viral infections using hydrogen sulfide donors
WO2016012470A1 (fr) 2014-07-25 2016-01-28 F. Hoffmann-La Roche Ag Nouvelles formes amorphes et cristallines de l'acide (3s)-4-[[(4r)-4-(2-chloro-4-fluorophényl)-5-méthoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]méthyl]morpholine-3-carboxilique
JP6506836B2 (ja) 2014-08-14 2019-04-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染症の処置および予防のための新規ピリダゾンおよびトリアジノン
TWI698444B (zh) 2014-10-29 2020-07-11 美商基利科學股份有限公司 製備核糖苷的方法
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
WO2016102438A1 (fr) 2014-12-23 2016-06-30 F. Hoffmann-La Roche Ag Procédé de préparation d'analogues de 4-phényl-5-alcoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidine
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
EP3240537B1 (fr) 2014-12-30 2020-09-09 F. Hoffmann-La Roche AG Nouvelles tétrahydropyridopyrimidines et tétrahydropyridopyridines pour le traitement et la prévention d'une infection par le virus de l'hépatite b
CN107109497A (zh) 2014-12-31 2017-08-29 豪夫迈·罗氏有限公司 通过实时PCR从细胞裂解物定量HBV cccDNA的高通量新方法
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
EP3250685A1 (fr) 2015-01-27 2017-12-06 F. Hoffmann-La Roche AG Adnccc du virus de l'hépatite b (hbv) recombiné, procédé pour générer ce dernier et utilisation associée
JP6435054B2 (ja) 2015-02-11 2018-12-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染の治療及び予防のための新規２−オキソ−６，７−ジヒドロベンゾ［ａ］キノリジン−３−カルボン酸誘導体
DK3349758T3 (da) * 2015-09-16 2022-06-13 Gilead Sciences Inc Fremgangsmåder til behandling af arenaviridae-virusinfektioner
WO2017184668A1 (fr) 2016-04-20 2017-10-26 Gilead Sciences, Inc. Méthodes de traitement d'infections virales à flaviviridae
CN108299532B (zh) 2016-12-29 2020-12-22 广东东阳光药业有限公司 一种抗病毒核苷类似物前药及其组合物、用途
BR112019016316A2 (pt) 2017-02-08 2020-03-31 Biotron Limited Métodos para o tratamento da influenza
CN110869028B (zh) 2017-03-14 2023-01-20 吉利德科学公司 治疗猫冠状病毒感染的方法
EP4219513A1 (fr) 2017-05-01 2023-08-02 Gilead Sciences, Inc. Forme cristalline de (s)-2-éthylbutyl 2-((s)-((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f! [1,2,4 triazin-7-yl)-5-cyano-3,4-dihydroxy tétrahydrofuranne 2-yl)méthoxy)(phénoxy) phosphoryl)amino)propanoate
CN111093627B (zh) 2017-07-11 2024-03-08 吉利德科学公司 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
CN111265532A (zh) 2020-01-21 2020-06-12 中国人民解放军军事科学院军事医学研究院 取代氨基丙酸酯类化合物在治疗2019-nCoV感染中的应用
KR20220132608A (ko) 2020-01-27 2022-09-30 길리애드 사이언시즈, 인코포레이티드 SARS CoV-2 감염증을 치료하기 위한 방법
TWI785528B (zh) 2020-03-12 2022-12-01 美商基利科學股份有限公司 1’-氰基核苷之製備方法
JP7482250B2 (ja) 2020-04-06 2024-05-13 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノ置換カルバヌクレオシド類似体の吸入製剤
EP4157272B1 (fr) 2020-05-29 2025-07-02 Gilead Sciences, Inc. Remdésivir pour le traitement des infections virales
US11926645B2 (en) 2020-08-27 2024-03-12 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Also Published As

Publication number Publication date
CY1125294T1 (el) 2025-03-28
SI3785717T1 (sl) 2022-04-29
HUE057928T2 (hu) 2022-06-28
PL3349758T3 (pl) 2022-09-12
DK3785717T3 (da) 2022-03-21
AU2020233714A1 (en) 2020-10-08
CY1125089T1 (el) 2023-06-09
US11007208B2 (en) 2021-05-18
AU2020233714B2 (en) 2022-11-24
JP7254738B2 (ja) 2023-04-10
PT3349758T (pt) 2022-07-13
MA42819A (fr) 2018-07-25
WO2017049060A1 (fr) 2017-03-23
EP3349758B1 (fr) 2022-04-06
JP2026122993A (ja) 2026-07-29
US20190255085A1 (en) 2019-08-22
EP4088718A1 (fr) 2022-11-16
AU2016323604A1 (en) 2018-03-29
HUE058737T2 (hu) 2022-09-28
HRP20220355T1 (hr) 2022-05-13
CN114366745A (zh) 2022-04-19
LT3785717T (lt) 2022-04-11
HRP20220740T1 (hr) 2022-11-11
MX2018003161A (es) 2018-05-17
HK1257628A1 (zh) 2019-10-25
JP2021107431A (ja) 2021-07-29
US20170071964A1 (en) 2017-03-16
US10695361B2 (en) 2020-06-30
AU2016323604B2 (en) 2020-07-09
ES2909419T3 (es) 2022-05-06
DK3349758T3 (da) 2022-06-13
ES2918585T3 (es) 2022-07-19
CN116617233A (zh) 2023-08-22
SI3349758T1 (sl) 2022-08-31
KR20180050742A (ko) 2018-05-15
JP2020111587A (ja) 2020-07-27
US10251904B2 (en) 2019-04-09
CN108348526A (zh) 2018-07-31
CN115887465A (zh) 2023-04-04
TW201733595A (zh) 2017-10-01
EA038141B1 (ru) 2021-07-13
US20230027727A1 (en) 2023-01-26
JP6742403B2 (ja) 2020-08-19
MX394858B (es) 2025-03-24
CN115844896B (zh) 2026-03-17
SG10202109869XA (en) 2021-10-28
MX382221B (es) 2025-03-13
CA2998189A1 (fr) 2017-03-23
SG10202001878WA (en) 2020-04-29
BR112018005048B1 (pt) 2021-02-23
JP2024081784A (ja) 2024-06-18
BR122020020217B1 (pt) 2021-08-17
BR112018005048B8 (pt) 2021-03-23
EP3349758A1 (fr) 2018-07-25
AU2023200990A1 (en) 2023-03-23
LT3349758T (lt) 2022-07-11
EA201890494A1 (ru) 2018-10-31
JP2023085459A (ja) 2023-06-20
PT3785717T (pt) 2022-04-14
JP2018531227A (ja) 2018-10-25
CN108348526B (zh) 2025-04-25
PL3785717T3 (pl) 2022-05-02
HK1255732A1 (zh) 2019-08-23
US11382926B2 (en) 2022-07-12
CA2998189C (fr) 2021-08-03
CN115844896A (zh) 2023-03-28
AU2025204785A1 (en) 2025-07-17
EP3785717B1 (fr) 2022-01-05
EP3785717A1 (fr) 2021-03-03
MX2021005087A (es) 2022-08-18
HK1256872A1 (en) 2019-10-04
US20210393659A1 (en) 2021-12-23
US20200352967A1 (en) 2020-11-12
AU2023200990B2 (en) 2025-04-10

Similar Documents

Publication Publication Date Title
EP3285776A4 (fr) Méthodes de traitement d&#39;infections bactériennes
MA46954A (fr) Méthodes de traitement d&#39;états inflammatoires
SI3785717T1 (sl) Postopki za zdravljenje okužb s Coronaviridae
MA50264A (fr) Méthodes de traitement des infections de type hépatite b
EP3370721A4 (fr) Traitement de l&#39;ostéoarthrite
EP3423488A4 (fr) Méthodes de traitement du cancer
EP3288383A4 (fr) Méthodes de traitement du cancer
MA45192A (fr) Traitement d&#39;association
EP3478286A4 (fr) Méthodes de traitement du cancer de l&#39;ovaire
EP2991638A4 (fr) Méthodes de traitement des infections bactériennes
EP3388004A4 (fr) Instrument de traitement
MA41119A (fr) Méthodes de traitement de syndromes myélodysplasiques et d&#39;anémie sidéroblastique
MA44083A (fr) Composés de biarylmonobactame pour le traitement d&#39;infections bactériennes
EP3302379A4 (fr) Compositions et méthodes pour le traitement du ptérygion
EP3519833A4 (fr) Méthodes de pronostic et de traitement
EP3362065A4 (fr) Polythérapie pour le traitement de malignités
EP3389634A4 (fr) Méthodes de traitement du cancer
EP3405203A4 (fr) Méthodes de traitement du cancer
MA53882A (fr) Méthodes de traitement de la sclérose en plaques
EP3512524A4 (fr) Méthodes et compositions de traitement d&#39;infections virales
EP3455188C0 (fr) Procede de traitement de laitier
EP3606531A4 (fr) Méthodes de traitement du cancer
EP3454793A4 (fr) Bobines de traitement d&#39;anévrisme
EP3383857A4 (fr) Composés et méthodes de traitement d&#39;infections bactériennes
EP3440112A4 (fr) Méthodes de traitement du cancer